Business Context and Reporting Period
Company: Neogen Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended February 28, 2009
Business Overview: Neogen operates two reportable segments: Food Safety (diagnostic test kits for food producers) and Animal Safety (veterinary instruments, rodenticides, and disinfectants). The company is an accelerated filer incorporated in Michigan.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Feb 28, 2009 |
Three Months Ended Feb 29, 2008 |
Nine Months Ended Feb 28, 2009 |
Nine Months Ended Feb 29, 2008 |
|---|---|---|---|---|
| Net Sales | $27,840 | $25,180 | $87,831 | $75,299 |
| Gross Margin | $13,027 (46.8%) | $12,663 (50.3%) | $43,956 (50.0%) | $39,131 (52.0%) |
| Operating Income | $3,571 (12.8%) | $3,981 (15.8%) | $15,085 (17.2%) | $13,326 (17.7%) |
| Net Income | $2,823 | $2,658 | $10,457 | $8,923 |
| Diluted EPS | $0.19 | $0.18 | $0.69 | $0.60 |
| Cash from Operations | N/A | N/A | $6,371 | $6,306 |
| Cash & Equivalents | $13,731 | $14,270 | $13,731 | $11,093 |
| Total Debt | $0 | $0 | $0 | $0 |
Note: Debt is zero as the company has a $10 million unsecured revolving line of credit with no amounts drawn as of February 28, 2009.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% for the quarter and 17% for the nine-month period compared to the prior year.
- Food Safety: Sales increased 2% (quarter) and 7% (nine months). Growth was driven by Bacteria & General Sanitation products (+13% quarter, +15% nine months), partially offset by declines in Dehydrated Culture Media.
- Animal Safety: Sales surged 20% (quarter) and 29% (nine months). This was primarily due to the acquisition of the DuPont disinfectant business, which drove Rodenticides & Disinfectants sales up 168% (quarter) and 92% (nine months).
- Margin Compression: Gross margins declined from 50.3% to 46.8% (quarter) and 52.0% to 50.0% (nine months). This was attributed to product mix changes from acquisitions (which have lower initial margins) and unfavorable currency translation effects (strengthening U.S. dollar).
- Operating Expenses: Operating expenses increased in absolute dollars but decreased as a percentage of revenue due to sales growth outpacing cost increases. R&D expenses increased as a percentage of sales (4.5% vs 4.0% in the quarter) due to strategic investment.
- Acquisitions: Significant cash outflows of $7.672 million for investing activities were driven by the DuPont acquisition and the formation of a Mexican subsidiary.
Guidance, Outlook, and Risks
- Guidance: Neogen explicitly states it does not provide forecasts of future performance. Management is optimistic about long-term prospects but notes historical results may not be indicative of future performance.
- Liquidity: Management believes existing cash ($13.7 million) and the $10 million credit facility are sufficient for foreseeable needs. However, future commercialization of products or acquisitions may require equity issuance or additional financing.
- Key Risks & Contingencies:
- Currency Risk: Significant exposure to the British Pound and Euro; a strengthening U.S. dollar negatively impacts reported sales.
- Supply Chain: Backorders of $425,000 in vitamin injectables due to supplier issues; FDA policy changes removed Isoxuprene from the equine market, costing over $500,000 in year-to-date sales.
- Customer Concentration: Inventory adjustments by a major international distributor negatively impacted Natural Toxins sales in the prior quarter, though sales returned to historical patterns in Q3.
- Legal: Subject to normal legal proceedings; management does not expect a material effect on operations.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline for transitioning DuPont disinfectant products from "buy-sell" to internally produced to confirm margin recovery expectations.
- Supply Chain Resolution: Monitor the status of the $425,000 backorder for vitamin injectables and the impact of the FDA Isoxuprene ban on future Animal Safety revenue.
- Currency Hedging: Review the effectiveness of forward currency exchange contracts in mitigating the impact of the strengthening U.S. dollar on European sales.
- Stock Repurchase: Note that 50,000 shares were purchased under the new buyback program subsequent to the reporting period (post-Feb 28, 2009).
- Intangible Assets: Assess the valuation of goodwill ($36.88 million) and intangible assets given the recent acquisitions and potential impairment risks if economic conditions deteriorate.